首页|丹红注射液联合泮托拉唑钠对呼吸衰竭急性加重期患者的疗效及安全性

丹红注射液联合泮托拉唑钠对呼吸衰竭急性加重期患者的疗效及安全性

扫码查看
目的 探讨呼吸衰竭急性加重期患者应用丹红注射液联合泮托拉唑钠治疗的临床效果及安全性.方法 选取浙江省中医院下沙院区2016年1月~2017年1月收治的104例呼吸衰竭急性加重期患者,采用随机数字表法均分为2组.2组均给予一致的基础治疗,对照组在此基础上予以泮托拉唑钠治疗,治疗组在对照组基础上加用丹红注射液治疗.记录比较2组临床疗效及不良反应情况.结果 治疗15 d后,治疗组总有效率为94.2%,较对照组(71.2%)显著升高(P<0.05).对照组和治疗组不良反应的发生率相比差异无统计学意义.结论丹红注射液联合泮托拉唑钠应用于治疗呼吸衰竭急性加重期中疗效显著且具有较高的安全性.
The efficacy and safety of Danhong injection combined with pantoprazole sodium on patients with acute exacerbation of respiratory failure
Objective To investigate the clinical efficacy and safety of Danhong injection combined with pantoprazole sodium on patients with acute exacerbation of respiratory failure. Methods 104 patients with acute exacerbation of respiratory failure were treated in our hospital from January 2016 to January 2017. They were selected and equally divided into two groups with the method of random number table. The two groups were given the same basic treatment, and the control group was treated with pantoprazole sodium on this basis. The treatment group was treated with Danhong injection on the basis of the control group. The clinical efficacy and adverse reactions of two groups were recorded. Results After 15 days of the treatment, the total effective rate of the treatment group was 94.2%, which was significantly higher than that of the control group 71.2%(P<0.05). There was no significant difference in the incidence of adverse reactions between the control group and the treatment group. Conclusion Danhong injection combined with pantoprazole sodium is effective and safe in the treatment of acute exacerbations of respiratory failure, which is worthy of clinical practice and popularization.

Danhong injectionpantoprazole sodiumacute exacerbation of respiratory failureclinical efficacysafety

刁闽俐、刘亚粉

展开 >

浙江省中医院下沙院区 急救创伤中心,浙江 杭州 310016

丹红注射液 泮托拉唑钠 呼吸衰竭急性加重期 临床疗效 安全性

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(10)
  • 3
  • 10